Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses

Stock News

07/22

Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.

According to the lapsed document, Bonsun Pharmaceuticals is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1170452620"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170452620\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170452620?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170452620","market":"nz","top_or_hot":-1,"title":"Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses","media":"Stock News","content":"<p>Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.<br><br>According to the lapsed document, <b>Bonsun Pharmaceuticals</b> is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBonsun Pharmaceuticals' Hong Kong IPO Prospectus Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-22 09:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.<br><br>According to the lapsed document, <b>Bonsun Pharmaceuticals</b> is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"","article_id":"1170452620","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170452620","pubTimestamp":1784683099,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","KCAI":"KraneShares China Alpha Index ETF","REDS":"RPM Republican Senate ETF","FRHC":"Euronext CAC Health Care","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","IPOS":"Renaissance International IPO ETF","BK4127":"投资银行业与经纪业","KCE":"SPDR KBW Capital Markets ETF"},"translate_title":"邦生制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"01477":1,"KCAI":1,"VXUS":1,"REDS":1,"KCE":1,"FRHC":1},"content_text":"Hong Kong-listed pharmaceutical company Bonsun Pharmaceuticals' IPO prospectus has expired. The prospectus for Hangzhou Bonsun Pharmaceuticals Co., Ltd., submitted to the Hong Kong Stock Exchange on January 22, 2026, has lapsed as of July 22, 2026, after the standard six-month validity period. China Securities (International) Corporate Finance Limited was the sole sponsor for the offering.According to the lapsed document, Bonsun Pharmaceuticals is a biotechnology company focused on the fields of oncology and autoimmune diseases. The company has established a pipeline that includes one New Drug Application (NDA) stage candidate (Bezexitinib), one registration-stage clinical candidate (CX1440), and five preclinical-stage candidates (CX03, CX12, CX13, CX15, and CX16).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}